Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 12, 2012, Pages 5901-5921

  Kulagowski, Janusz J ^a   Blair, Wade ^b,e   Bull, Richard J ^a   Chang, Christine ^b   Deshmukh, Gauri ^b   Dyke, Hazel J ^a   Eigenbrot, Charles ^b   Ghilardi, Nico ^b   Gibbons, Paul ^b   Harrison, Trevor K ^a   Hewitt, Peter R ^a   Liimatta, Marya ^b   Hurley, Christopher A ^a   Johnson, Adam ^b   Johnson, Tony ^a   Kenny, Jane R ^b   Bir Kohli, Pawan ^b   Maxey, Robert J ^a   Mendonca, Rohan ^b   Mortara, Kyle ^b   Murray, Jeremy ^b   Narukulla, Raman ^a   Shia, Steven ^b   Steffek, Micah ^b   Ubhayakar, Savita ^b   Ultsch, Mark ^b   Van Abbema, Anne ^b   Ward, Stuart I ^a   Waszkowycz, Bohdan ^c,d   Zak, Mark ^b   more..

^a Early Discovery Charles River   (United Kingdom)

^b GENENTECH INC   (United States)

^c Department of Infectious Disease MedImmune ^*  (United Kingdom)

^d MEDIMMUNE   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 METHANESULFONYL 4 METHYL PIPERIDIN 4 YL) 1,6 DIHYDROIMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE; 1 (1 METHANESULFONYL PIPERIDIN 4 YL) 1,6 DIHYDRO IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE; 1 (4 METHYLPIPERIDIN 4 YL) 1,6 DIHYDRO IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE; 1 [(1 PHENYLMETHYL)PIPERIDIN 4 YL] 1,6 DIHYDRO IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE; 1 ISOPROPYLPYRROLIDIN 2 YL [4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) PIPERIDIN 1YL]METHANONE; 1 PIPERIDIN 4 YL 1,6 DIHYDRO IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE; 4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) (PIPERIDIN 1 YL)PROPANENITRILE; 4 AMINOPYRIDINE DERIVATIVE; 4 METHYL 4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) PIPERIDINE 1 CARBOXYLIC ACID TERT BUTYL ESTER; CIS 1 [4 METHYL 1 (PHENYLMETHYL) PIPERIDIN 3 YL] 1,6 DIHYDRO IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDINE; CIS 3 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) 4 METHYLPIPERIDIN 1 YL) 3 OXOPROPANENITRILE; IMIDAZOPYRIDINE DERIVATIVE; JANUS KINASE 1; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2; JANUS KINASE INHIBITOR; N [1 (PHENYLMETHYL)PIPERIDIN 4 YL] 5 NITRO 1 (PHENYLSULFONYL) 1H PYRROLO[2,3 B]PYRIDIN 4 AMINE; TRANS 3 [4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) CYCLOHEXYLAMINO]PROPIOINITRILE; TRANS 4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) CYCLOHEXYLAMINE; TRANS [3 (6 PHENYLSULFONYL IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) CYCLOPENTYL]CARBAMIC ACID TERT BUTYL ESTER; TRANS [4 (6 PHENYLSULFONYL 4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) CYCLOHEXYL]CARBAMIC ACID TERT BUTYL ESTER; TRANS [4 (IMIDAZO[4,5 D]PYRROLO[2,3 B]PYRIDIN 1(6H) YL) CYCLOHEXYL]CARBAMIC ACID TERT BUTYL ESTER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CELL LINE; IMIDAZOLES; JANUS KINASE 1; JANUS KINASE 2; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; RATS; SUBSTRATE SPECIFICITY;

EID: 84863109520     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300438j     Document Type: Article

References (65)

1. Song, L.; Schindler, C. JAK-STAT Signalling. In The Handbook of Cell Signalling. 2 nd ed.; Bradshaw, R. A., Dennis, E. A., Eds.; Elsevier Inc.: San Diego, CA, 2010; Vol. 3, pp 2041-2048.
2. Shuai, K.; Liu, B. Regulation of JAK-STAT Signalling in the Immune System Nat. Rev. Immunol. 2003, 3, 900-911
3. Ghoreschi, K.; Laurence, A.; O'Shea, J. J. Janus Kinases in Immune Cell Signalling Immunol. Rev. 2009, 228, 273-287
4. Levy, D. E.; Darnell, J. E., Jr. STATS: Transcriptional Control and Biological Impact Nat. Rev. Mol. Cell Biol. 2002, 3, 651-662
5. Kisseleva, T.; Bhattacharya, S.; Braunstein, J.; Schindler, C. W. Signalling Through the JAK/STAT Pathway, Recent Advances and Future Challenges Gene 2002, 285, 1-24
6. Schindler, C.; Levy, D. E.; Decker, T. JAK-STAT Signaling: From Interferons to Cytokines J. Biol. Chem. 2007, 282, 20059-20063
7. Quintas-Cardama, A.; Kantarjian, H.; Cortes, J.; Verstovsek, S. Janus Kinase Inhibitors for the Treatment of Myeloproliferative Neoplasias and Beyond Nat. Rev. Drug Discovery 2011, 10, 127-140
8. Watford, W. T.; O'Shea, J. J. Human TYK2 Kinase Deficiency: Another Primary Immunodeficiency Syndrome Immunity 2006, 25, 695-697
9. O'Shea, J. J.; Gadina, M.; Schreiber, R. D. Cytokine Signaling in 2002: New Surprises in the Jak/Stat Pathway Cell 2002, 109 (Suppl.) S121-S131
10. O'Shea, J. J.; Pesu, M.; Borie, D. C.; Changelian, P. S. A New Modality for Immunosuppression: Targeting the JAK/STAT Pathway Nat. Rev. Drug Discovery 2004, 3, 555-564
11. Wrobleski, S. T.; Pitts, W. J. Advances in the Discovery of Small Molecule JAK3 Inhibitors. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.: Elsevier Inc.: San Diego, 2009; Vol. 44, Chapter 12, pp 247-264.
12. Changelian, P. S.; Flanagan, M. E.; Ball, D. J.; Kent, C. R.; Magnuson, K. S.; Martin, W. H.; Rizzuti, B. J.; Sawyer, P. S.; Perry, B. D.; Brissette, W. H.; McCurdy, S. P.; Kudlacz, E. M.; Conklyn, M. J.; Elliott, E. A.; Koslov, E. R.; Fisher, M. B.; Strelevitz, T. J.; Yoon, K.; Whipple, D. A.; Sun, J.; Munchhof, M. J.; Doty, J. L.; Casavant, J. M.; Blumenkopf, T. A.; Hines, M.; Brown, M. F.; Lillie, B. M.; Subramanyam, C.; Shang-Poa, C.; Milici, A. J.; Beckius, G. E.; Moyer, J. D.; Su, C.; Woodworth, T. G.; Gaweco, A. S.; Beals, C. R.; Littman, B. H.; Fisher, D. A.; Smith, J. F.; Zagouras, P.; Magna, H. A.; Saltarelli, M. J.; Johnson, K. S.; Nelms, L. F.; Des Etages, S. G.; Hayes, L. S.; Kawabata, T. T.; Finco-Kent, D.; Baker, D. L.; Larson, M.; Si, M. S.; Paniagua, R.; Higgins, J.; Holm, B.; Reitz, B.; Zhou, Y. J.; Morris, R. E.; O'Shea, J. J.; Borie, D. C. Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor Science 2003, 302, 875-878
13. West, K. CP-690550, a JAK3 Inhibitor as an Immunosuppressant for the Treatment of Rheumatoid Arthritis, Transplant Rejection, Psoriasis and Other Immune-mediated Disorders Expert Opin. Invest. Drugs 2009, 10, 491-504
14. Verstovsek, S. Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms J. Clin. Oncology 2011, 29, 781-788
15. Vijayakrishnan, L.; Venkataramanan, R.; Gulati, P. Treating Inflammation with the Janus Kinase Inhibitor CP-690,550 Trends Pharmacol. Sci. 2011, 32, 25-34
16. Meyer, D. M.; Jesson, M. I.; Li, X.; Elrick, M. M.; Funckes-Shippy, C. L.; Warner, J. D.; Gross, C. J.; Dowty, M. E.; Ramaiah, S. K.; Hirsch, J. L.; Sabbye, M. J.; Barks, J. L.; Kishore, N.; Morris, D. L. Anti-Inflammatory Activity and Neutrophil Reductions Mediated by the JAK1/JAK3 Inhibitor, CP-690,550, in Rat Adjuvant-Induced Arthritis J. Inflamm. 2010, 7, 41
17. Lucia, E.; Recchia, A. G.; Gentile, M.; Bossio, S.; Vigna, E.; Mazzone, C.; Madeo, A.; Morabito, L.; Gigliotti, V.; DeStefano, L.; Caruso, N.; Servillo, P.; Franzese, F.; Bisconte, M. G.; Gentile, C.; Morabito, F. Janus Kinase 2 Inhibitors in Myeloproliferative Disorders Expert Opin. Invest. Drugs 2011, 20, 41-59
18. Ghoreschi, K.; Laurence, A.; O'Shea, J. J. Selectivity and Therapeutic Inhibition of Kinases: To Be or Not To Be? Nat. Immunol. 2009, 4, 356-360
19. Mesa, R. A.; Yasothan, U.; Kirkpatrick, P. Ruxolitinib Nat. Rev. Drug Discovery 2012, 11, 103-104
20. Moreland, L. A Randomized Placebo-Controlled Study of INCB018424, a Selective Janus Kinase 1& 2 (JAK1&2) Inhibitor in Rheumatoid Arthritis (RA). Annual Scientific Meeting of the American College of Rheumatology, San Francisco, CA, Oct 24-29, 2008; John Wiley & Sons: Chichester, UK; Abstract 714.
21. Quintas-Cardama, A.; Vaddi, K.; Liu, P.; Manshouri, T.; Li, J.; Scherle, P. A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.; Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers, J. D.; Haley, P.; Kantarjian, H.; Fridman, J. S.; Verstovsek, S. Preclinical Characterization of the Selective JAK1/2 Inhibitor INCB01424: Therapeutic Implications for the Treatment of Myeloproliferative Neoplasms Blood 2010, 115, 3109-3117
22. Haan, C.; Rolvering, C.; Raulf, F.; Kapp, M.; Druckes, P.; Thoma, G.; Behrmann, I.; Zerwes, H.-G. Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors Chem. Biol. 2011, 18, 314-323
23. Rodig, S. J.; Meraz, M. A.; White, J. M.; Lampe, P. A.; Riley, J. K.; Arthur, C. D.; King, K. L.; Sheehan, K. C. F.; Yin, L.; Pennica, D.; Johnson, E. M., Jr; Schreiber, R. D. Disruption of the JAK1 Gene Demonstrates Obligatory and Nonredundant Roles of the JAKs in Cytokine-Induced Biologic Responses Cell 1998, 93, 373-383
24. Parganas, E.; Wang, D.; Stravopodis, D.; Topham, D. J.; Marine, J.-C.; Teglund, S.; Vanin, E. F.; Bodner, S.; Colamonici, O. R.; van Deursen, J. M.; Grosveld, G.; Ihle, J. N. JAK2 Is Essential for Signaling Through a Variety of Cytokine Receptors Cell 1998, 93, 385-395
25. Shimoda, K.; Kato, K.; Aoki, K.; Matsuda, T.; Miyamoto, A.; Shibamori, M.; Yamashita, M.; Numata, A.; Takase, K.; Kobayashi, S.; Shibata, S.; Asano, Y.; Gondo, H.; Sekiguchi, K.; Nakayama, K.; Nakayama, T.; Okamura, T.; Okamura, S.; Niho, Y.; Nakayama, K. TYK2 Plays a Restricted Role in IFN± Signaling, Although it is Required for IL-12-Mediated T Cell Function Immunity 2000, 13, 561-571
26. Patel, A. M.; Moreland, L. W. Interleukin-6 Inhibition for Treatment of Rheumatoid Arthritis: A Review of Tocilizumab Therapy Drug Des. Dev. Ther. 2010, 4, 263-278
27. Baslund, B.; Tvede, N.; Danneskiold-Samsoe, B.; Larsson, P.; Panavi, G.; Petersen, J.; Petersen, L. J.; Beurskens, F. J.; Schuuman, J.; van de Winkel, J. G.; Parren, P. W.; Gracie, J. A.; Jongbloed, S.; Liew, F. Y.; McInnes, I. B. Targeting Interleukin-15 in Patients With Rheumatoid Arthritis: A Proof-of-Concept Study Arthritis Rheum. 2005, 52, 2686-2692
28. Yamaoka, K.; Kubo, S.; Sonomoto, K.; Maeshima, K.; Tanaka, Y. JAK Inhibitor: Tofacitinib, a New Disease Modifying Anti-Rheumatic Drug Inflammation Regener. 2011, 31, 349-353
29. Fleischmann, R.; Cutolo, M.; Genovese, M. C.; Lee, E. B.; Kanik, K. S.; Sadis, S.; Connell, C. A.; Gruben, D.; Krishnaswami, S.; Wallenstein, G.; Wilkinson, B. E.; Zwillich, S. H. Phase 2B Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) or Adalimumab Monotherapy Versus Placebo in Patients with Active Rheumatoid Arthritis with an Inadequate Response to DMARDs Arthritis Rheum. 2012, 64, 617-629
30. Kremer, J. M.; Cohen, S.; Wilkinson, B. E.; Connell, C. A.; French, J. L.; Gomez-Reino, J.; Gruben, D.; Kanik, K. S.; Krishnaswami, S.; Pascuala-Ramos, V.; Wallenstein, G.; Zwillich, S. H. A Phase 2B Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination with Background Methotrexate in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Alone Arthritis Rheum. 2012, 64, 970-981
31. Jatiani, S. S.; Baker, S. J.; Silverman, L. R.; Reddy, E. P. JAK/STAT Pathways in Cytokine Signaling and Myeloproliferative Disorders: Approaches for Targeted Therapies Genes Cancer 2010, 1, 979-993
32. Verstovsek, S.; Passamonti, F.; Rambaldi, A.; Barosi, G.; Rosen, P.; Levy, R.; Bradley, E. C.; Schacter, L.; Garrett, W. M.; Vaddi, K.; Contel, N.; Rumi, E.; Gattoni, E.; Cazzola, M.; Kantarjian, H.; Barbui, T.; Vannucchi, A. A Phase 2 Study of INCB018424, an Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea; 51st American Society of Hematology Annual Meeting and Exposition, New Orleans, LA, Dec 5-8, 2009; American Society of Hematology: Washington, DC; Abstract 311.
33. Neubauer, H.; Cumano, A.; Muller, M.; Wu, H.; Huffstadt, U.; Pfeffer, K. Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis Cell 1998, 93, 397-409
34. Garber, K. Pfizer's JAK Inhibitor Sails Through Phase 3 in Rheumatoid Arthritis Nat. Biotechnol. 2011, 29, 467-468
35. Jiang, J.; Ghoreschi, K.; Deflorian, F.; Chen, Z.; Perreira, M.; Pesu, M.; Smith, J.; Nguyen, D.-C.; Liu, E. H.; Leister, W.; Costanzi, S.; O'Shea, J. J.; Thomas, J. T. Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3 R,4 R)-4-methyl-3-(methyl(7H-pyrrolo[2,3- d ]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550) J. Med. Chem. 2008, 51, 8012-8018
36. Flanagan, M. E.; Blumenkopf, T. A.; Brissette, W. H.; Brown, M. F.; Casavant, J. M.; Shang-Poa, C.; Doty, J. L.; Elliott, E. A.; Fisher, M. B.; Hines, M.; Kent, C.; Kudlacz, E. M.; Lillie, B. M.; Magnuson, K. S.; McCurdy, S. P.; Munchhof, M. J.; Perry, B. D.; Sawyer, P. S.; Strelevitz, T. J.; Subramanyam, C.; Sun, J.; Whipple, D. A.; Changelian, P. S. Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection J. Med. Chem. 2010, 53, 8468-8484
37. Williams, N. K.; Bamert, R. S.; Patel, O.; Wang, C.; Walden, P. M.; Fantino, E.; Rossjohn, J.; Lucet, I. S. Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domain J. Mol. Biol. 2009, 387, 219-232
38. Inoue, T.; Tanaka, A.; Nakai, K.; Sasaki, H.; Takahashi, F.; Shirakami, S.; Hatanaka, K.; Nakajima, Y.; Mukoyoshi, K.; Hamaguchi, H.; Kunikawa, S.; Higashi, Y. Heterocyclic Janus Kinase 3 Inhibitors. WO2007077949, 2007. More recently, during the course of this work, patent applications have appeared describing other tricyclic, azaindole-containing scaffolds as JAK inhibitors. These include azaindole annelated by pyrrole
39. Shirakami, S.; Nakajima, Y.; Maeda, J.; Tominaga, H.; Yamagishi, H.; Hondo, T.; Inami, M.; Morio, H.; Inoue, T.; Mizutani, T.; Ishioka, H. Fused Pyrrolopyridine Derivative. WO2010119875, 2010; by pyrrole, pyrazole, and isoxazole
40. Wishart, N.; Argiriadi, M.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S.; Li, B. C.; Morytko, M. J.; Stewart, K. D.; Voss, J. W.; Wallace, G. A.; Wang, L.; Woller, K. R. Novel Tricyclic Compounds. WO2009152133, 2009; by isothiazole, triazole, and imidazole, as in 3
41. Wishart, N.; Argiriadi, M.; Breinlinger, E. C.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S.; Li, B. C.; Morytko, M. J.; Mullen, K. D.; Somal, G.; Stewart, K. D.; Voss, J. W.; Wallace, G. A.; Wang, L.; Woller, K. R. Novel Tricyclic Compounds. WO2011068899, 2011. Tricycles corresponding to 3 but having distinct substitution and probably employing an alternative hinge-binding mode have recently appeared as JAK2 inhibitors
42. Purandare, A. V.; Grebinski, J. W.; Hart, A.; Inghrim, J.; Schroeder, G.; Wan, H. JAK2 Inhibitors and Their Use for the Treatment of Myeloproliferative Diseases and Cancer. WO2011028864, 2011.
43. Acker, B. A.; Hartmann, S. J.; Huang, H.-C.; Jacobsen, E. J.; Promo, M. A.; Wolfson, S. G.; Xie, J. Pyrrolo[2,3-d]pyrimidine Compounds. WO2011045702, 2011, and
44. Xie, J.; Promo, M. A.; Jacobsen, E. J.; Huang, H.-C.; Maddux, T. Pyrrolo[2,3-D]pyrimidine Compounds. WO2011075334, 2011. Also claimed as JAK1 selective inhibitors are derivatives of 2
45. Huang, T.; Xue, C.-B.; Wang, A.; Kong, L.; Ye, H. F.; Yao, W.; Rodgers, J. D.; Shepard, S.; Wang, H.; Shao, L.; Li, H.-Y.; Li, Q. Piperidin-4-yl Azetidine Derivatives as JAK1 Inhibitors. WO2011112662, 2011
46. Rodgers, J. D.; Li, Y.-L.; Shepard, S.; Wang, H. Heterocyclic Derivatives of Pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as Janus Kinase Inhibitors. WO2011028685, 2011
47. Li, Y.-L.; Rodgers, J. D. 3-[4-(7 H -Pyrrolo[2,3-d]pyrimidin-4-yl)-1 H -pyrazol-1-yl]octane- or Heptane-nitrile As JAK Inhibitors. WO2010135621, 2010, along with a polyaryl macrocycle
48. Combs, A. P.; Sparks, R. B.; Yue, E. W.; Feng, H.; Bower, M. J.; Zhu, W. Macrocyclic Compounds and Their Use as Kinase Inhibitors. WO2009132202, 2009.
49. Van't Klooster, G.; Van Rompaey, L.; Menet, C.; Namour, F.; Vanhoutte, F.; van der Aar, E.; Clément-Lacroix, P.; Gallien, R.; Nelles, L.; Guérin, C.; Smets, B.; Brys, R.; Feyen, J.; Wigerinck, P. Preclinical Pharmacology and Early Clinical Evaluation of GLPG0634, a Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis. EULAR Annual European Congress of Rheumatology, London, May 25-28, 2011; BMJ Publishing Group Ltd.: London; Abstract 251.
50. Galapagos' GLPG0634 Shows Excellent Efficacy and Safety in Rheumatoid Arthritis Phase II Study. Galapagos NV: Mechelen, Belgium, Press Release November 22, 2011. Available at http://www.glpg.com/.
51. Malerich, J. P.; Lam, J. S.; Hart, B.; Fine, R. M.; Klebansky, B.; Tanga, M. J.; D'Andrea, A. Diamino-1,2,4-triazole Derivatives Are Selective Inhibitors of TYK2 and JAK1 Over JAK2 and JAK3 Bioorg. Med. Chem. Lett. 2010, 20, 7454-7457
52. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Cicero, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A Quantitative Analysis of Kinase Inhibitor Selectivity Nat. Biotechnol. 2008, 26, 127-132
53. Van Abbema, A.; Kanada, H.; Chang, C.; Bir Kohli, P.; Smith, J.; Barrett, K.; Lewin-Koh, N.; Johnson, A. R.; Ghilardi, N.; Blair, W. Determination of the JAK-Dependence of Cytokine Pathways Using Small Molecule Inhibitors, unpublished results.
54. Chrencik, J. E.; Patny, A.; Leung, I. K.; Korniski, B.; Emmons, T. L.; Hall, T.; Weinberg, R. A.; Gormley, J. A.; Williams, J. M.; Day, J. E.; Hirsch, J. L.; Kiefer, J. R.; Leone, J. W.; Fischer, H. D.; Sommers, C. D.; Huang, H.-C.; Jacobsen, E. J.; Tenbrink, R. E.; Tomasselli, A. G.; Benson, T. E. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP690550 and CMP-6 J. Mol. Biol. 2010, 400, 413-433
55. The Pymol Molecular Graphics System, version 1.3; Schrödinger, LLC: New York (http://www.pymol.org).
56. Wang, X.; Zhi, B.; Baum, J.; Chen, Y.; Crockett, R.; Huang, L.; Eisenberg, S.; Ng, J.; Larsen, R.; Martinelli, M.; Reider, P. A Practical Synthesis of 2-((1 H -Pyrrolo[2,3-b]pyridine-4-yl)methylamino)-5-fluoronicotinic Acid J. Org. Chem. 2006, 71, 4021-4023
57. Vanotti, E.; Angelucci, F.; Bargiotti, A.; Brasca, M. G.; Menichincheri, M. Pyrrolopyridines as Kinase Inhibitors. WO2007054508, 2007.
58. Brown Ripin, D. H.; Abele, S.; Cai, W.; Blumenkopf, T.; Casavant, J. M.; Doty, J. L.; Flanagan, M.; Koecher, C.; Laue, K. W.; McCarthy, K.; Meltz, C.; Munchhof, M. J.; Pouwer, K.; Sha, B.; Sun, J.; Teixeira, J.; Vries, T.; Whipple, D. A.; Wilcox, G. Development of a Scaleable Route for the Production of cis-N -Benzyl-3-methylamino-4-methylpiperidine Org. Process Res. Dev. 2003, 7, 115-120
59. Ramadas, K.; Srinivasan, N. Iron-Ammonium Chloride: A Convenient and Inexpensive Reductant Synth. Commun. 1992, 22, 3189-3195
60. Li, F.; Brogan, J. B.; Gage, J. L.; Zhang, D.; Miller, M. J. Chemoenzymatic Synthesis and Synthetic Application of Enantiopure Aminocyclopentenols: Total Synthesis of Carbocyclic (+)-Uracil Polyoxin C and Its ±-Epimer J. Org. Chem. 2004, 69, 4538-4540
61. Ranganathan, S.; George, K. S. 2-Aza-3-oxabicyclo[2.2.1]heptane Hydrochloride: An Exceptionally Versatile Synthon For Carbocyclic Sugars and Nucleosides Tetrahedron 1997, 53, 3347-3362
62. Gregson, M.; Ayres, B. E.; Ewan, G. B.; Ellis, F.; Knight, J. 2,6-Diaminopurine Derivatives. WO199417090, 1994.
63. Erickson, S. D.; Qian, Y.; Tilley, J. W. Diaminocyclohexane and Diaminocyclopentane Derivatives. WO2008065021, 2008.
64. Morrison, J. F. Kinetics of the Reversible Inhibition of Enzyme-Catalyzed Reactions by Tight-binding Inhibitors Biochim. Biophys. Acta 1969, 185, 269-296
65. William, J. W.; Morrison, J. F. The Kinetics of Reversible Tight-binding Inhibition Methods Enzymol. 1979, 63, 437-467